Vanderbilt University School of MedicineDisclosures
Dr. Roden receives royalties on a patent related to predicting drug-induced arrhythmias. He is currently a consultant to Merck, Novartis, Astellas, Sanofi, Dai-ichi Sankyo.
|Program Name||Last Air Date||Hosts/Guests|
|Genetic Testing for Long QT Syndrome||01/30/2018|
|DNA Biobanks Empowering Personalized Medicine||03/17/2016|
|Drug Response Variability: Toward Customized Treatments for Arrhythmias||02/26/2016|
You need to be logged in to save this episode to a playlist.
You must be logged in to display playlists.